NEW YORK (GenomeWeb News) – Cancer genetics testing company Neogenomics said on Thursday that revenues during the second quarter rose 49 percent year over year as test volume increased 57 percent.

For the period ended June 30, revenues totaled $15.6 million, up from $10.5 million a year ago as the number of tests performed jumped to 28,846 from 18,358.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.

At her blog, Sally Rockey dives into National Institutes of Health funding data.